Dr Ankur Kalra’s guest this week is Dr Saraschandra Vallabhajosyula, Interventional and Critical Care Cardiologist, Assistant Professor of Medicine at the Warren Alpert Medical School of Brown University and the Director of the Cardiac Intensive Care Unit at Rhode Island Hospital, the Miriam Hospital and Lifespan Cardiovascular Institute. In this episode of Parallax, they delve into the latest insights from ACC.24 through the lens of five pivotal late-breaking trials.
Dr Vallabhajosyula offers a deep dive into the nuances of each study. Together, Dr Kalra and Dr Vallabhajosyula distil the complexities of these trials into key messages for practice, grounded in their own clinical experiences.
In the spotlight are five key trials:
1. DanGer Shock: Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock
2. RELIEVE-HF: Safety and effectiveness of the V-Wave® Ventura® Interatrial Shunt for the treatment of heart failure (HF)
3. PREVENT: Preventive PCI or medical therapy alone for vulnerable atherosclerotic coronary plaque
4. REDUCE AMI: Decreased usage of beta-blockers after acute myocardial infarction
5. ORBITA-COSMIC: Coronary sinus reducer for the treatment of refractory angina
Dr Kalra and Dr Vallabhajosyula dissect the practical implications of these trials, answering pressing questions and addressing emerging dilemmas. What are the key takeaways from ACC.24? How do these findings shape contemporary clinical practice?
Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode.
Guest: @SarasVallabhMD Host: @AnkurKalraMD and produced by: @RadcliffeCARDIO
Together, Dr Kalra and Dr Darlington delve into the significance of assessing volume status in patients with heart failure, highlighting its continued relevance in 2024, including the availability of new diagnostic tools, including the Heart Failure Management System (HFMS).
This series is supported by ZOLL and is intended for Health Care Professionals.
This series is supported by ZOLL and is intended for Health Care Professionals.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Ankur and Madhav also discuss positive traits of leadership, why we should embrace failure and the importance of mentorship throughout all stages of one’s medical career. Send us your comments to this episode for Ankur to share in future episodes: pocast@radciffe-group.com. Guest @mswami001.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Harriette is an Associate Professor of Medicine at the Department of Medicine, Cardiology and the Department of Health Research Methods, Evidence and Impact at McMaster University and the Population Health Research Institute in Hamilton, ON, Canada. In this episode, Ankur and Harriette discuss why this issue is so contentious, what the current state of medical walls represents, why this may be an issue and what alternative medical walls could look like. Harriette also shares her thoughts on how this topic relates to the maintenance of hierarchical power structures in academic institutions, calling for more collaborative leadership and management styles. Guest @hvanspall.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
In this episode, Ankur and Danielle speak about the evidence in favour of a whole-food plant-based diet to improve cardiovascular health, the ACC prevention guidelines, how to talk to patients about positive dietary change, the issue of lack of nutrition training in cardiovascular fellowships and what Danielle’s diet looks like as a busy whole-food plant-based cardiology fellow. On her own podcast ‘Nutrition Rounds’ Danielle has discussions about evidence-based plant-based nutrition with physicians who are leading experts in nutrition and health.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
In this brilliant conversation, Ankur, Emmanouil and Michael unravel the potential advantages, challenges and practical realities of using drug-coated balloons in SVD, and the findings of the latest randomised controlled trials studying this area.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology. [Disclaimer: The use of drug-coated balloons in coronay intervention is still off-label; it has not been approved by the FDA.]